We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

By MedImaging International staff writers
Posted on 23 Apr 2014
Print article
An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography).

Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked closely with a number of Radiologists at a world renowned healthcare organization to clinically validate the solution prior to submitting to the FDA. This builds upon their previous clearances for diagnosis using web, iOS, and Android devices.

“We chose to implement ResolutionMD because it gives us the ability to quickly disseminate the images from our Pediatric Imaging Departments so that clinicians can provide the fastest and best care and treatment to our patients,” said Stuart Royal, MS, MD, radiologist-in-chief at Children’s Hospital of Alabama. “Their fully accredited, diagnostic image quality and secure solution gives us the flexibility to make clinical decisions from any device type, portable or desktop throughout our healthcare system and off-site.”

The FDA’s safety and effectiveness review of ResolutionMD found it to be substantially equivalent to PACS or dedicated diagnostic workstations, giving practitioners access to advanced image storage systems and diagnostic tool sets on-the-go. Gaining this clearance means a healthcare enterprise, across all departments, can feel confident in using ResolutionMD to perform a clinical diagnosis on web, iOS and Android devices, as it has been through a rigorous testing process, as agreed to by the FDA.

“We are excited to deliver this clearance to the institutions that rely on ResolutionMD to improve patient care,” said Pierre Lemire, president and CTO of Calgary Scientific. “This is also an important advancement for all our valued partners including those who deliver custom-branded solutions, as they will be added under the Calgary Scientific registration with the FDA.”

ResolutionMD enables doctors to securely view patient images and reports from a wide variety of computers and mobile devices, collaborate with other practitioners, and diagnose from any location. The FDA-cleared, Health Canada-licensed, and CE marked mobile medical diagnosis software can be integrated into any EMR and easily plugs into existing distributed storage systems.

ResolutionMD’s federated approach is an important differentiator from other solutions as highly sensitive data is never moved to a device and no additional data storage locations are created. ResolutionMD is published in twelve languages and is currently installed in leading healthcare institutions around the world via a network of more than thirty-five world class healthcare partners.

Calgary Scientific is a developer of web and mobile diagnostic medical imaging and cloud-enabling solutions.

Related Links:

Calgary Scientific


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
Acclarix AX9
New
Breast Imaging Workstation
SecurView
New
X-Ray Detector
FDR-D-EVO III

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.